【Chugai Pharmaceutical】2026 Mid-Year Financial Results｜Sales of 663.3 billion yen (Up 14.7% YoY)

Performance Overview

Chugai Pharmaceutical achieved mid-year 2026 results with sales of 663.3 billion yen (up 14.7% YoY), operating profit of 319.6 billion yen (up 16.9%), and net income of 231.7 billion yen (up 19.2%). Revenue from both domestic and international products was strong, with overseas sales increasing by 14.1% to 328.6 billion yen. R&D expenses reached 90.2 billion yen, supporting new drug approvals and expanded indications. The dividend was increased to 66 yen, further strengthening shareholder returns.

Outlook and Impact on Shareholders

For the full year of 2026, sales are projected to be 1.345 trillion yen (up 6.9% YoY), with net income of 485 billion yen (up 7.5%). The company will continue to promote R&D investments and new drug approvals for sustained growth. The dividend remains at 66 yen, emphasizing shareholder returns. For investors, the steady performance coupled with proactive R&D investments presents an attractive outlook.